Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Random

Display 15 Products per page

Disease Analysis: Crohn’s Disease
Read More
Crohn’s disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active.
October 7, 2021
Find out more
Galvus
Read More
Galvus (vildagliptin; Novartis) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.
November 7, 2017
Find out more
Global Markets for Hospital-Based Point-of-Care Diagnostic Products

$4,750.00

In 2015, the global point-of-care (POC) clinical diagnostic products market was valued at $14.7bn, comprising 28% of the total in-vitro diagnostics (IVD) market. The market is projected to grow at a somewhat slower rate than the overall IVD market, due mainly to a decline in the overall blood glucose self-testing segment, which comprises more than half of the POC diagnostics market.
November 11, 2016
Find out more
Treanda/Bendeka
Read More
Treanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent.
January 31, 2019
Find out more
Market Spotlight: Cachexia

$1,318.00

Cachexia is a complex, multifactorial, and multi-organ metabolic syndrome found in the late stages of serious illnesses including cancer, kidney disease, and congestive heart failure.
March 8, 2022
Find out more
Non-Small Cell Lung Cancer KOL Interview

$599.00

Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.
December 16, 2016
Find out more
Leukemia KOL Insight and Pulse Survey Bundle

$1,099.00

The second-generation TKIs dasatinib and nilotinib are increasingly being used as frontline therapy for CML; this expert gives imatinib only to patients with co-morbidities.
September 8, 2017
Find out more
Gilenya
Read More
Gilenya is a synthetic derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb isaria sinclarii which acts as a potent agonist at four of the S1P receptors (S1P1, S1P3, S1P4, and S1P5).
November 24, 2017
Find out more
Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK

$599.00

In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.
October 12, 2018
Find out more
CRO Snapshot: Clinical Outsourcing in 2012

$5,000.00

By any standards, last year was a turbulent one for the pharmaceutical sector. The patent cliff claimed some of the industry’s most profitable properties and with the market share of these drugs losing ground to generics, put even more pressure on the top- and bottom-line performance of key players such as Eli Lilly and AstraZeneca, to name just two of the worst hit.

Such pressure – and the drive to cut fixed costs that goes with it – has been a boon for clinical CROs, which have become increasingly indispensable to the business of drug discovery, as clinical development is outsourced and specialist units, such as clinical laboratories, are offloaded to CROs in long-term guaranteed strategic partnerships.
November 3, 2016
Find out more
blisibimod
Read More
Blisibimod is a selective antagonist of B-cell activating factor (BAFF)/B lymphocyte stimulator (BLyS) that is in Phase III development for SLE. Elevated levels of BAFF have also been associated with several B-cell-mediated autoimmune diseases including…
April 5, 2016
Find out more
Head and Neck Cancer KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.
April 14, 2020
Find out more
Victoza
Read More
Victoza (liraglutide; Novo Nordisk) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.
July 7, 2017
Find out more
Coumadin
Read More
Coumadin is an orally available vitamin K antagonist (VKA) indicated for the prophylaxis and

treatment of deep vein thrombosis and pulmonary embolism.
August 2, 2016
Find out more
Exelon
Read More
Novartis first launched Exelon as a twice-daily oral formulation in Europe in 1998 and in the US in 2000 for the treatment of mild to moderate Alzheimer’s disease.
September 2, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *